US Patent

US8664215 — Ocular allergy treatments with alcaftadine

Method of Use · Assigned to Vistakon Pharmaceuticals LLC · Expires 2027-12-23 · 2y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects compositions, kits, and methods for treating or preventing ocular allergies and inflammation with alcaftadine or a pharmaceutically acceptable salt thereof.

USPTO Abstract

Compositions, kits, and methods for the treatment or prevention of ocular allergies and inflammation and the symptoms thereof containing alcaftadine or a pharmaceutically acceptable salt thereof.

Drugs covered by this patent

Lastacaft (ALCAFTADINE) · AbbVie

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3267`	—	Lastacaft

Patent Metadata

Patent number: US8664215
Jurisdiction: US
Classification: Method of Use
Expires: 2027-12-23
Drug substance claim: No
Drug product claim: No
Assignee: Vistakon Pharmaceuticals LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.